These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 20638206)

  • 1. [Persistent influenza virus infection in a patient treated with alemtuzumab].
    Burrel S; Dilhuydy S; Bouabdallah K; Lafon MÉ; Milpied N; Fleury H
    Med Mal Infect; 2010 Nov; 40(11):657-9. PubMed ID: 20638206
    [No Abstract]   [Full Text] [Related]  

  • 2. Campath-1H induced pure red cell aplasia in a patient with chronic lymphatic leukaemia.
    Thachil J; Salim R
    Leuk Res; 2007 Jul; 31(7):1025-6. PubMed ID: 17005249
    [No Abstract]   [Full Text] [Related]  

  • 3. Late onset of autoimmune hemolytic anemia and pure red cell aplasia after allogeneic hematopoietic stem cell transplantation using in vivo alemtuzumab.
    Kako S; Kanda Y; Oshima K; Nishimoto N; Sato H; Watanabe T; Hosoya N; Motokura T; Miyakoshi S; Taniguchi S; Kamijo A; Takahashi K; Chiba S; Kurokawa M
    Am J Hematol; 2008 Mar; 83(3):247-9. PubMed ID: 17918251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Red cell aplasia due to parvovirus b19 in a patient treated with alemtuzumab.
    Crowley B; Woodcock B
    Br J Haematol; 2002 Oct; 119(1):279-80. PubMed ID: 12358942
    [No Abstract]   [Full Text] [Related]  

  • 5. Pure red-cell aplasia due to parvovirus B19 infection in a patient treated with alemtuzumab.
    Herbert KE; Prince HM; Westerman DA
    Blood; 2003 Feb; 101(4):1654. PubMed ID: 12560244
    [No Abstract]   [Full Text] [Related]  

  • 6. Tuberculosis due to Mycobacterium bovis after alemtuzumab administration.
    Abad S; Gyan E; Moachon L; Bouscary D; Sicard D; Dreyfus F; Blanche P
    Clin Infect Dis; 2003 Jul; 37(2):e27-8. PubMed ID: 12856232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treatment for chronic lymphocytic leukaemia.
    Anoop P; Wotherspoon A; Matutes E
    Br J Haematol; 2010 Feb; 148(3):484-6. PubMed ID: 19874308
    [No Abstract]   [Full Text] [Related]  

  • 8. Alemtuzumab for B-cell chronic lymphocytic leukemia.
    Robak T
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1033-51. PubMed ID: 18588450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute cutaneous T-cell lymphoma transformation during treatment with alemtuzumab.
    Faguer S; Launay F; Ysebaert L; Mailhol C; Estines-Chartier O; Lamant L; Paul C
    Br J Dermatol; 2007 Oct; 157(4):841-2. PubMed ID: 17714563
    [No Abstract]   [Full Text] [Related]  

  • 10. The development of sarcoidosis with the use of alemtuzumab - clues to T-cell immune reconstitution.
    Thachil J; Jadhav V; Gautam M; McKew S; Arumainathan A; Collins D; Smyth C; Harper J; Pettitt A
    Br J Haematol; 2007 Aug; 138(4):559-60. PubMed ID: 17587337
    [No Abstract]   [Full Text] [Related]  

  • 11. Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia.
    Au WY; Lam CC; Chim CS; Pang AW; Kwong YL
    Leuk Res; 2005 Oct; 29(10):1213-5. PubMed ID: 16111536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refractory idiopathic pure red cell aplasia complicated by immune thrombocytopenia successfully treated with subcutaneous alemtuzumab.
    Pham DC; Guthrie TH; Villas BH; Salazar E
    Am J Hematol; 2008 Jul; 83(7):603. PubMed ID: 18273896
    [No Abstract]   [Full Text] [Related]  

  • 13. An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab.
    Ghobrial IM; Otteman LA; White WL
    N Engl J Med; 2003 Dec; 349(26):2570-2; discussion 2570-2. PubMed ID: 14695424
    [No Abstract]   [Full Text] [Related]  

  • 14. Epstein-barr virus-positive diffuse large B-cell lymphoma during therapy with alemtuzumab for T-cell prolymphocytic leukemia.
    Sohani AR; Ferry JA; Chang PS; Abramson JS
    J Clin Oncol; 2010 Feb; 28(5):e69-72. PubMed ID: 19917859
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-glomerular basement membrane disease after alemtuzumab.
    Clatworthy MR; Wallin EF; Jayne DR
    N Engl J Med; 2008 Aug; 359(7):768-9. PubMed ID: 18703487
    [No Abstract]   [Full Text] [Related]  

  • 16. Remission of pure red cell aplasia in T-cell receptor gammadelta-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab.
    Schützinger C; Gaiger A; Thalhammer R; Vesely M; Fritsche-Polanz R; Schwarzinger I; Ohler L; Simonitsch-Klupp I; Reinhard F; Jäger U
    Leukemia; 2005 Nov; 19(11):2005-8. PubMed ID: 16193089
    [No Abstract]   [Full Text] [Related]  

  • 17. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.
    O'Brien SM; Keating MJ; Mocarski ES
    Clin Lymphoma Myeloma; 2006 Sep; 7(2):125-30. PubMed ID: 17026823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycobacterium avium complex infection after alemtuzumab therapy for chronic lymphocytic leukemia.
    Saadeh CE; Srkalovic G
    Pharmacotherapy; 2008 Feb; 28(2):281-4. PubMed ID: 18225973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fatal case of alemtuzumab-associated interstitial pneumonitis.
    Creelan B; Ferber A
    Am J Ther; 2008; 15(1):82-4. PubMed ID: 18223357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycobacterium haemophilum infection after alemtuzumab treatment.
    Kamboj M; Louie E; Kiehn T; Papanicolaou G; Glickman M; Sepkowitz K
    Emerg Infect Dis; 2008 Nov; 14(11):1821-3. PubMed ID: 18976587
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.